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ost-traumatic stress disorder (PTSD) is a disor-
der where patients are haunted by their traumatic mem-
ories. For a patient with PTSD, it is as if time has
stopped. It could be 10, 20 (or even more) years after the
exposure, yet he/she is still there, reliving, re-experienc-
ing, and retraumatized by the event which changed his
or her life so dramatically.
What is a traumatic event which could lead to PTSD? In
DSM-IV, such an event was defined as “an event or
events that involved actual or threatened death or seri-
ous injury, or a threat to the physical integrity of self or
others.”
1 However, as such a description might leave too
much room for different interpretations, the intention in
DSM-5 is to tighten this up somewhat. One suggestion is
to specify that the event involves death, serious physical
injury, or sexual violation (either actual or threatened),
and that this exposure takes the form of a personal expe-
rience, first-hand witnessing of the event as it occurred
to others, learning of the event as it occurred to a close
friend or relative, or repeated exposure to the event as
it occurred to others (such as to police officers or para-
medics repeatedly exposed to the traumatic experiences
of others).
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Post-traumatic stress disorder (PTSD) is unique amongst
psychiatric disorders in two ways. Firstly, there is usually a
very clear point of onset—the traumatic event. The second
unique feature of PTSD is that it is characterized by a fail-
ure of the normal response to resolve. Given these two
characteristics, PTSD appears a good candidate for sec-
ondary prevention, ie, interventions immediately after the
trauma. Evidence available starting from current concepts
and contemporary research of potential secondary pre-
vention interventions are presented. Common practices in
the aftermath of trauma such as debriefing and benzodi-
azepines need to be carefully considered, taking into
account their potential harm to the spontaneous recovery
process, and the trajectory of PTSD, and not only judging
them according to their immediate (comforting) effects. A
discussion of the balance required between aiding recov-
ery but not interfering with the potent natural resolution
of symptoms (that is expected in most cases), along with
potential avenues of future research, are presented. Results
of a small pilot study with a single intervention of hydro-
cortisone immediately after trauma appear to be promis-
ing, and clearly indicate the need for further studies.      
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requirement—at least a month following the trauma—
which means that one cannot diagnose PTSD during the
first month after the exposure. Acute PTSD is consid-
ered if the symptoms last more than a month and up to
3 months (if it is more than 3 months, it is defined as
chronic PTSD—Figure 1). Beyond the actual presence
of the relevant symptoms, the sixth criterion for clinical
diagnosis of PTSD is clinically significant distress or
impairment of functioning, which is a common denom-
inator for all anxiety disorders.
In the minds of many, PTSD is related to mega-events
such as 9/11, tsunami, war, etc. However, the major con-
tributors to PTSD are actually daily civilian events, such
as car accidents, work-related accidents, violence, and
armed robbery, to name a few. PTSD can also occur after
exposure to a serious illness (for example myocardial
infarction). In modern civilian life, exposure to traumatic
events (that might lead to PTSD) is prevalent. In fact,
about 50% of the (Western) population would have
been exposed to a traumatic event that might later on
lead to PTSD during their lifetime.
2
What is unique about PTSD is that the vast majority
(80% to 90%) of those exposed to this type of trauma
will eventually adapt. Only 10% to 20% become fixated
on the event, and develop PTSD.
3 If 50% of the popula-
tion are exposed at some point of their life to traumatic
events, and if on average 15% of them will develop
PTSD, then the expected prevalence of PTSD in the
population would be 7.5%. Indeed, in the National
Comorbidity Survey,
2 the prevalence was found to be
6.8%, while in earlier studies the prevalence ranged
from 7.8% to 8.7%
3-5 (Figure 2).
What are the risk factors for PTSD?
Pretraumatic risk factors
A meta-analysis of risk factors
6 proposed trauma inten-
sity as an important factor, along with previous trau-
matic history,
7 family history of psychiatric disorders,
8,9
personal history of emotional or psychiatric disorders
prior to the trauma, history of substance abuse, and
poorer intellectual abilities.
10 In a semiprospective study
conducted by our group,
11 we compared 2362 war veter-
ans who developed PTSD with an equal number of war
veterans who did not develop PTSD. Comparisons were
made on predrafting personal factors and pretrauma
army characteristics. The intention was to find out
whether careful predrafting cognitive and behavioral
screening would help to predict who will develop PTSD.
It turned out that neither behavioral assessment, includ-
ing measures such as socioeconomic background and
motivation to serve, nor training were found to predict
PTSD. Hence, predraft screening done at age 17 failed
to predict who would develop PTSD either during their
mandatory service (age 18 to 21), or during reserve
duties (age 21 to 49). The only exception was a border-
line significance related to intelligence, which in any case
measures the ability of individuals to adapt, and is there-
fore believed to be a nonspecific mediator.
Post-traumatic risk factors
The intensity and magnitude of the immediate response
to the traumatic event are associated with increased risk
of developing PTSD. Reactions like dissociative symp-
Figure 1. Time course and post-traumatic stress disorder (PTSD) subtypes.
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Figure 2. Lifetime prevalence of post-traumatic stress disorder in the com-
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3-5
7.94
8.75
7.83
%
302
Pharmacological aspects
PAGES_ 12_AG_1004_BA.qxd:DCNS#50  30/08/11  16:04  Page 302toms, panic-like response, extreme withdrawal, psy-
chotic-like symptoms, and suicidality all raise red flags
regarding the person's vulnerability to developing
PTSD.
11
Why is PTSD suitable for prevention?
PTSD is different from other psychiatric disorders, in that
it has a very clear point of onset. In most cases, the trau-
matic event is also the point of onset of symptoms. The
second unique feature of PTSD is that it is characterized
by a failure of the normal response to disappear. The
expected response after exposure to a traumatic event is
to experience shock, horror fear, terror, grief, etc. This is
a normal response to an abnormal situation. It becomes
a disorder when this normal response continues (accord-
ing to DSM-IV, for more than a month). Moreover, as
mentioned earlier, the vast majority (80% to 90%) expe-
rience spontaneous recovery from these symptoms, and
hence, one way to conceptualize PTSD is as a disorder
where there is a failure to recover (Figure 3). If PTSD is
a failure to recover, then our obligation, as clinicians, to
the patient is primum non nocere (“First, do no harm” ),
ie, not to interfere with the potent spontaneous recovery
process which usually takes place. It seems that what we
do in this “window of opportunity,” in those “golden
hours”—the first few hours after the exposure to the
traumatic event—might have the potential to dramati-
cally alter the trajectory of PTSD.
Memory and PTSD
We submit that the main feature of PTSD is the trau-
matic memory, which is clinically expressed by criterion
B of the DSM-IV, namely that the traumatic event is
persistently re-experienced through recurrent and intru-
sive distressing recollections and/or recurrent distress-
ing dreams, acting or feeling as if the traumatic event
were recurring (including dissociative flashback
episodes) and intense psychological distress and physi-
ological reactivity upon exposure to internal or external
cues that symbolize or resemble an aspect of “the event.” 
Thus, the core pathology of PTSD is the re-experienc-
ing—the distressing recollections, flashbacks, nightmares,
etc. One way to describe this is that patients with PTSD
are haunted by the memory of the event. For them, the
past is always present; it is as if the clock has stopped,
and they are constantly either reliving the experience, or
fighting very hard not to be exposed to triggers which
might set off a flashback. The avoidance, numbing, and
increased arousal would then be secondary phenomena.
One question would be regarding the consolidation of
the traumatic event. Consolidation is the transition from
unstable to stable memory, and the question is, if we
could prevent this consolidation, whether or not it would
be beneficial.
When individuals with traumatic brain injury with amne-
sia of the traumatic events were compared with those
without amnesia, it was found that 6% of those with
amnesia of the traumatic presented PTSD symptoms at
a 6-month follow-up, as opposed to 23% in those with-
out amnesia.
12 This naturalistic study suggests that
impaired memory for the traumatic event reduces the
risk for PTSD.
Repressive coping style and PTSD
A repressive coping style is a cognitive and emotional
strategy aimed at ignoring or diverting attention from a
threat
13 and, in a way, could mimic amnesia. If the
hypothesis is that amnesia for traumatic events reduces
the rate of PTSD, we would expect that individuals with
repressive coping styles would be less vulnerable to
developing PTSD. Indeed, in a study of prevalence of
PTSD after MI,
14 it was found that in individuals with
repressive coping style the prevalence of PTSD was
lower (7.1%), as compared with individuals with low
anxiety (20%), high anxiety (19.4%) or defensive cop-
ing style (17.2%)—Table I.
Actually, the possibility that repressive coping style
could be an adaptive way of dealing with trauma has
been known for close to 30 years.
15This observation was
described as follows: “Avoidance, suppression, and denial
Figure 3. Most people exposed to trauma do not develop post-traumatic
stress disorder.
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traumatic stress-induced distress.”
Debriefing and spontaneous remission
If a reduction in fear memory associated with the trauma
is beneficial, then psychological interventions which
enhance memories of the trauma, eg, debriefing, would
interfere with the potent beneficial spontaneous recov-
ery. In a study of psychological debriefing for road traf-
fic accident victims,
16 it was found in a follow-up 4 months
and 3 years after the accident, that a subset of individu-
als—those who experienced high anxiety after the acci-
dent and received debriefing—were doing significantly
worse (as measured by Impact of Event Score), 4 months
and 3 years later, as compared with those who did not
receive the debriefing. That is, the expected and welcome
spontaneous recovery process was hampered by this
intervention, which is associated with enhancing memo-
ries of the traumatic event. Other studies
17-20 also reported
similar findings, and a meta-analysis
21 also supported the
caution that one should exercise in indiscriminate uti-
lization of single-session debriefing. 
Amnesia and medications
What about medications which might have a potential
effect on consolidation of the traumatic memory? How
would intervention with medication which modulates
consolidation of emotional memory fit with the theme
that reduction in fear memory associated with trauma is
beneficial?
It is quite common to use benzodiazepine (BNZ) in
order to calm down the horror and fear associated with
exposure to a traumatic event. However, BNZ is associ-
ated with enhancing access to emotional memories (but
not to procedural memory). Actually, until the 1970s, one
of the major techniques to treat PTSD was via the “ben-
zodiazepine interview,” which used BNZ (or sodium pen-
tothal) in order to help the individual to go through full
re-experience of the event. However, how does this fit
with our line of reasoning that reducing fear memory is
beneficial? In a small study, Gelpin et al
22 compared at 1-
and 6-month follow-up individuals who received BNZ
(clonazepam 2.6 mg/day or alprazolam 2.5 mg/day) with
those who did not receive it. Out of the 13 who received
BNZ, 9 developed PTSD, as compared with 3 of the 13
controls. These findings were also replicated by Mellman
et al in a small study.
23 In a unique animal model, which
is based on setting affected (rats) apart from the unaf-
fected,
24 administration of alprazolam 1 hour after the
exposure was associated with significantly more extreme
behavioral response (the behavioral equivalent of PTSD)
for the rats who were given alprazolam as compared with
those who got saline.
25 Hence, some pilot human data,
plus a signal from animal studies suggest that early
administration of BNZ might interfere with the normal
potent spontaneous recovery.
Hypothalamic-pituitary-adrenal axis, PTSD, and BNZ
Glucocorticoids were found to reduce phobic fear in
humans.
26 Individuals with arachnophobia who were
injected with cortisol 1 hour before exposure reported
less fear (as measured on a visual analog scale) as com-
pared with individuals who got saline.
Stress is associated with activation of the hypothalamic-
pituitary-adrenal (HPA) axis, and consequently with
secretion of hydrocortisone. What is the effect of BNZ
on this normal, primary cornerstone of the normal
response to stress? What is the effect of BNZ on corti-
sol? Why does administration of BNZ seem to interfere
with the normal recovery process? Administration of
BNZ abolishes the expected activation (the normal
response) of the HPA axis. 
The HPA axis is the main component in the neuroen-
docrine response to acute and chronic stress (Figure 4).
In response to stress, a chain of reactions stimulates the
adrenal cortex to synthesize and release glucocorticoids,
in particular cortisol. These hormones are instrumental
in adaptation to stress.
27 A main function appears to be
in the regulation and containment of the sympathetic
and parasympathetic responses to stress (ie, changes in
heart rate, blood pressure, respiration), responses that
Repressive Low anxious High anxious Defensive
N=28 N=20 N=36 N=29
Subclinical ASD 14.3% 10% 27.8% 20.7%
Clinical ASD 3.6% 0% 36.1% 20.7%
Subclinical PTSD 10.7% 10% 44.4% 37.9%
Clinical PTSD 7.1% 20% 19.4% 17.2%
Table I. Repressive coping style. PTSD, post-traumatic stress disorder. 
Adapted from ref 14: Ginzburg K, Solomon Z, Bleich A. Repressive coping
style, acute stress disorder, and posttraumatic stress disorder after myocar-
dial infarction. Psychosom Med. 2002;64:748-757. Copyright © Lippincott
Willams and Wilkins 2002
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In animal studies, it has been demonstrated that blunted
HPA-axis response increased PTSD-like reactions in rats
exposed to trauma,
28 which strengthens the notion that
an intervention aimed at bolstering this natural response
with an early intervention immediately after the trauma
could help reduce PTSD (Figure 5).
However, the data supporting a potential low plasticity
of the HPA axis as a potential risk factor for PTSD does
not derive only from animal studies. In a study looking
at the trajectory of PTSD in motor accident victims,
29 it
was found that patients who developed PTSD had sig-
nificantly less urinary cortisol compared with individu-
als who experienced the same trauma, but did not
develop PTSD. Taking together the human and animal
data suggests that a proper reactivity (plasticity) of the
HPA axis is instrumental for spontaneous remission
after exposure to a traumatic event.
BNZs do exactly the opposite—they abolish the usual
HPA axis response, and it is conceivable that this might
have a calming effect to begin with, but in the long run
it might increase the risk of developing PTSD. A poten-
tial explanation for this might be associated, among
other activities, with the role of cortisol, not only in
decreasing the fear response, but also in its conceivable
role in consolidation of the traumatic memory. 
Cortisol administration in the “golden hours” 
The logical step at this point would be to see whether
early administration of cortisol would be associated with
secondary prevention of PTSD. Looking at a medical
setting where patients usually receive cortisol (as part of
their treatment) could provide us with a hint regarding
the question of the potential beneficial role of early
administration of cortisol after exposure to traumatic
events.
In an intensive care unit, after cardiac surgery, some
patients receive cortisol as part of their treatment.
Indeed it was found that those who were treated with
cortisol seemed to have significantly fewer traumatic
memories compared with those who did not.
30 This had
also been found in a study of septic shock patients.
31
Would an immediate, postexposure intervention clini-
cally affect the restoration of stability, encourage
resilience, and improve the ability to cope and thrive in
the face of adversity? Or, to put it differently, would
stress doses of hydrocortisone be useful for secondary
prevention of PTSD?
This question was tested in an animal model study,
32
which aimed to address the question of the value of pre-
scribing a single dose of cortisol, immediately after being
exposed to a traumatic event. The results were quite
impressive—medium-to-high doses of hydrocortisone
given 1 hour after exposure to the smell of a predator
were associated with significantly less “anxiety index” (a
measure which takes into account time spent in open
arms, time spent on exploration, and number of open-
arm entries). The finding suggests that early administra-
tion of corticosterone significantly decreased the vul-
nerability and increased resistance to PTSD, and that at
least a part of the effect is through involvement in mem-
ory consolidation.
Figure 4. The hypothalamic-pituitary-adrenal axis.
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immediately after the event, in this short window of
opportunity. Consequently, the question arises of
whether hydrocortisone administration would be useful
if not administered right after the exposure (in the
“golden hours”). When the same dose of cortisol was
administered 14 days after the stressor and 1 hour after
presenting a reminder, the results were strikingly differ-
ent. Cortisol given not in the “golden hours” was totally
ineffective in reducing the “anxiety index.” 
The current lack of prospective studies following the
lead of animal studies regarding the potential utility for
early administration of cortisol spurred us to initiate a
pilot study to examine this.
33 Three major points were
raised. The first was whether psychiatry has a “window
of opportunity” for treatment as in other medical fields
(ie, stroke or myocardial infarction). The second was
whether it would be possible to reach people within a
short time after the trauma and to give them the treat-
ment in a timely fashion. The third question is whether
a single medium to high dose of IV hydrocortisone (100
to 120 mg) would alter the trajectory of PTSD. In this
study, the window of opportunity was limited to the first
6 hours after the exposure, and consequently this was
done in the emergency room of a general hospital.
Patients who had a higher risk of developing PTSD were
selected, in order to have an enriched sample. To achieve
this, the patients selected were those fulfilling criteria A,
2 of the symptoms in criteria B, 3 out of 4 of criteria C,
D, E, and F, and meeting criterion H of the ASD criteria
set out in DSM-IV.
1
Twenty-five patients were recruited from the emergency
room; 20 after traffic accidents and 5 following other
civilian events. They were randomly assigned to treat-
ment with IV hydrocortisone (100 to 140 mg) (n=15) or
placebo (n=10). The patients were followed up by tele-
phone the day after the treatment, and then at 2 weeks,
1 month, and 3 months, with a personal interview includ-
ing the Clinician Administered PTSD Scale (CAPS).
Out of the 25 patients, 19 completed 2 weeks, 15 com-
pleted 1 month, and 17 completed the 3-month follow-
up. The results of this preliminary study suggest that cor-
tisol was effective in reducing both acute stress disorder
(20% in the cortisol group vs 66.7% in the placebo con-
dition) as well as rates of PTSD (12.5% vs 37.5% at 1-
month (ns), and 0% vs 37.5% at 3-month follow-up).
This is shown in Figure 6. 
The results reflect both the utility of the enriched sam-
ple concept, ie, in the placebo group, 37.5% had indeed
developed PTSD at 1- and 3-month follow up, and it also
points out the effect of early intervention with hydro-
cortisone, as only 12.5% at 1-month and none at 3-
month follow-up presented with PTSD.
There are other studies which look at long-term effects
of early administration of different pharmacological
interventions. The first one was a study by Pitman et al,
34
in which administration of propranolol for 10 days was
compared with placebo given in the same fashion. In this
study, supported also by the work of Debiec and
Ledoux,
35 a modest effect of early propranolol admin-
istration was found. However, follow-up studies failed to
replicate this initial positive yet modest response.
36,37
Another possibility explored as a potentially beneficial
“golden hours” intervention is related to morphine. A
lower rate of PTSD was found in a large retrospective
study which included 696 American soldiers in Iraq with
serious injuries, out of whom 243 developed PTSD and
453 did not.
38 The major finding is related to the differ-
ence in prevalence of morphine administration for those
two groups. A significantly lower percentage of individ-
uals got morphine in the PTSD group than in the group
that did not develop PTSD (61% vs 76% respectively).
This work is in line with an earlier small study with sim-
ilar findings.
39
Clinical implications
As it seems that traditional approaches like debriefing
and anxiolytics (BNZ) are not effective, and might actu-
Figure 6. Rates of acute stress disorder/post-traumatic stress disorder after
early administration of cortisol/placebo.
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clinician do for a patient who comes to the emergency
room after experiencing a trauma? We suggest differen-
tiating between acute stress management and acute
stress reaction treatment.
The acute stress management is not usually carried out
by mental health professionals, and should be designed
accordingly. The goals are to help the individual to
return to full functioning, help him or her to regain
behavioral and emotional control, and facilitate restora-
tion of interpersonal communication. The management
should focus on addressing basic needs. Firstly, reducing
the exposure to the stress (ie, finding a secure place, etc).
Secondly, restoring physiological needs (food, drink,
hygiene, etc), and also providing some information and
orientation, and helping to locate a source of support
(family, friends, etc) along with emphasizing the expec-
tation of returning back to normal. Alongside the actions
that need to be taken, there are interventions that
should not be done. This is summarized as the three Ps,
namely: don't Pathologize (“this is a normal response to
an abnormal situation”), don't Psychologize (don't facil-
itate emotional reaction via group therapy, or stressful
debriefing), and don't Pharmacologize (Table II).
40
The treatment goes along the same lines, with an empha-
sis on return to previous functioning via affirmation of
self-control and facilitation of return to previous activi-
ties. If the expected recovery does not take place after a
couple of months, then referral to specific psychological
intervention in the framework of cognitive behavioral
therapy should be explored.
41
Conclusion
PTSD is a severe, disabling disorder, with dramatic con-
sequences, both on the individual him- or herself and his
or her family. The core symptom is the traumatic mem-
ory, and the patient is constantly haunted by the mem-
ory of the event; for him or her the past is always pre-
sent. It is conceivable that the future of this disorder
would focus on the window of opportunity (“golden
hours”), ie, intervention in the first few hours after the
exposure. Whilst we continue the search for a “morning-
after pill,” it is important first to make sure that our
intervention does not interfere with the normal potent
recovery process which takes place in the majority of
patients. Along these lines, the contemporary knowledge
about debriefing and use of BNZ should be considered
at these stages. Interventions such as adrenergic med-
ication (like propranolol or morphine) have been stud-
ied. As for propranolol, replications of the data were not
encouraging, and morphine has its inherent conse-
quences, which should be taken into account. Animal
studies of cortisol appear promising, and the same is true
for pilot data in humans, but undoubtedly more work
should be done in order to better explore and conse-
quently improve our current strategies.
PTSD provides a unique opportunity for exploring sec-
ondary prevention in psychiatry, and from a disorder
that is often associated with guilt and accusations, it has
the potential to become a disorder where scientific
knowledge could open a window to dramatically chang-
ing its trajectory. ❏
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Don’t Pathologize: ie, “normal response to an abnormal situation”
Don’t Psychologize: ie,  don’t facilitate emotional reaction via 
group therapy, debriefing etc
Don’t Pharmacologize: ie, don’t use benzodiazepines or sleeping 
pills in the first few hours
Table II. What not to do; the “3P.”
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secundaria del TEPT
El trastorno por estrés postraumático (TEPT) es sin-
gular entre los trastornos psiquiátricos por dos
aspectos. Primero, porque habitualmente hay un
claro punto de inicio: el acontecimiento traumático.
El segundo aspecto singular del TEPT es que se
caracteriza por una falla en la respuesta normal de
resolución. Considerando estas dos características,
el TEPT aparece como un buen candidato para la
prevención secundaria, es decir, las intervenciones
inmediatamente después del trauma. Se presentan
las evidencias disponibles a partir de los conceptos
actuales y la investigación reciente acerca de las
potenciales intervenciones para la prevención
secundaria. Es necesario que las prácticas habitua-
les para las consecuencias del trauma como son el
debriefing y las benzodiazepinas sean consideradas
cuidadosamente, teniendo en cuenta el riesgo
potencial para el proceso de recuperación espon-
táneo, y la evolución del TEPT, y no calificarlas sólo
en relación con los efectos inmediatos (aliviadores).
Se presenta una discusión acerca del balance que
debe hacerse entre favorecer la recuperación y no
interferir con la potente resolución natural de los
síntomas (lo que se espera en la mayor parte de los
casos); además se discuten los potenciales caminos
para futuras investigaciones. Si bien parecen ser
promisorios los resultados de un pequeño estudio
piloto en que se empleó una dosis única de hidro-
cortisona inmediatamente después del trauma, es
claro que se requieren futuros estudios. 
Nouveautés dans la prévention secondaire
de l’ESPT
L’état de stress post-traumatique (ESPT) est un
trouble psychiatrique original par deux aspects.
Tout d’abord, son point de départ est habituelle-
ment très clair, l’événement traumatique. La
seconde caractéristique originale de l’ESPT se tra-
duit par un échec de la réponse normale pour le
résoudre. Ces deux caractéristiques font de l’ESPT
un bon candidat pour la prévention secondaire,
c’est-à-dire pour une intervention immédiate après
le traumatisme. Nous présentons ici les arguments
en faveur des interventions de prévention secon-
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